Symptoms with overall prevalence increasing from baseline to 3 months and increasing or remaining high at 6 months.

Baseline clinical characteristics of patients who were followed up for 6 months.

Hiroki Okabe (14425179)
Yoshitaka Muraoka (14425182)
Yutaro Naka (14425185)
Koshi Setoyama (14425188)
Konosuke Inoue (14425191)
Toshiya Miura (14425194)
Akiyoshi Shimizu (14425197)
Reo Anai (14425200)
Tetsu Miyamoto (14425203)
Yuki Tsuda (6391430)
Masaru Araki (14425206)
Shinjo Sonoda (9291701)
Masaharu Kataoka (290909)

January 2023

Baseline clinical characteristics of patients who were followed up for 6 months.</p

Incidence rates of symptoms during all the period of study by athlete status.

Natalia Rodriguez-Valero (5675603)
Miguel Luengo Oroz (5675606)
Daniel Cuadrado Sanchez (5675609)
Alexander Vladimirov (5675612)
Marina Espriu (5675615)
Isabel Vera (5675618)
Sergi Sanz (89754)
Jose Luis Gonzalez Moreno (5675621)
Jose Muñoz (3343469)
Maria Jesus Ledesma Carbayo (5675624)

August 2018

Incidence rates of symptoms during all the period of study by athlete status.</p

Disease and symptom prevalence estimates including 95% confidence intervals and unadjusted odds ratios.

H. Felix Fischer (457925)
Sylvia Binting (457926)
Angelina Bockelbrink (436852)
Peter Heusser (397715)
Christoph Hueck (457927)
Thomas Keil (177240)
Stephanie Roll (168590)
Claudia Witt (457928)

September 2013

Disease and symptom prevalence estimates including 95% confidence intervals and unadjusted odds r...

Fig 3 -

Terence Stephenson (3568832)
Snehal M. Pinto Pereira (14725336)
Manjula D. Nugawela (14725339)
Kelsey McOwat (13894193)
Ruth Simmons (558172)
Trudie Chalder (37639)
Tamsin Ford (492302)
Isobel Heyman (3579683)
Olivia V. Swann (14725342)
Lana Fox-Smith (14725345)
Natalia K. Rojas (14725348)
Emma Dalrymple (14725351)
Shamez N. Ladhani (4033334)
Roz Shafran (3579680)

March 2023

Symptoms with overall prevalence declining from baseline to 6 months post-test in test-positives*.</...

Distribution of symptoms at 3 months among study participants with post COVID-19 condition (n = 1,510).

Peter Seah Keng Tok (8748453)
Kong Yeow Kang (17743178)
Sock Wen Ng (14167608)
Norazida Ab Rahman (12267122)
Muhammad Aminul Syahmi (17743181)
Mohan Dass Pathmanathan (9319777)
Maheshwara Rao Appannan (14076732)
Kalaiarasu M. Peariasamy (9319780)
Sheamini Sivasampu (3580265)

January 2024

Distribution of symptoms at 3 months among study participants with post COVID-19 condition (n = 1,51...

Percentage of self-reported Long COVID symptoms at four weeks and six months of follow-up.

M. C. Arjun (14285136)
Arvind Kumar Singh (8808743)
Debkumar Pal (14285139)
Kajal Das (12895698)
Alekhya G. (14285142)
Mahalingam Venkateshan (14207855)
Baijayantimala Mishra (14285145)
Binod Kumar Patro (10151285)
Prasanta Raghab Mohapatra (10151300)
Sonu Hangma Subba (5689889)

December 2022

Percentage of self-reported Long COVID symptoms at four weeks and six months of follow-up.</p

Prevalence of metabolic syndrome, at baseline, three and six months, by randomization group.

Lotte van Dammen (4759953)
Vincent Wekker (4759959)
Anne M. van Oers (4759983)
Meike A. Q. Mutsaerts (4759980)
Rebecca C. Painter (4759956)
Aeilko H. Zwinderman (93416)
Henk Groen (444146)
Cornelieke van de Beek (4759974)
Anneke C. Muller Kobold (128867)
Walter K. H. Kuchenbecker (4759977)
Ron van Golde (4759965)
Gerrit J. E. Oosterhuis (4759968)
Niels E. A. Vogel (4759971)
Ben Willem J. Mol (3090126)
Tessa J. Roseboom (501394)
Annemieke Hoek (4759962)

January 2018

Prevalence of metabolic syndrome, at baseline, three and six months, by randomization group.</p

Prevalence of symptoms associated with AOM in children enrolled at baseline (day 0).

Penelope Abbott (3502094)
Caitlin Frede (14670762)
Wendy C. Y. Hu (10907179)
Sanja Lujic (316280)
Steven Trankle (7048088)
Letitia Campbell (12421633)
Hasantha Gunasekera (8295636)
Robyn Walsh (14670765)
Amanda J. Leach (12415702)
Peter Morris (86687)
Kelvin Kong (10983062)
Jennifer Reath (5572118)

February 2023

Prevalence of symptoms associated with AOM in children enrolled at baseline (day 0).</p

Prevalence (%) of symptoms in patients with different conditions at baseline interview.

Irene J. Higginson (121358)
Wei Gao (2085)
Tariq Zaffer Saleem (121362)
K. Ray Chaudhuri (121366)
Rachel Burman (50700)
Paul McCrone (121370)
Peter Nigel Leigh (121374)

November 2012

Prevalence (%) of symptoms in patients with different conditions at baseline interview.</p

Factors associated with development of post COVID-19 condition at 3 months interval.

Peter Seah Keng Tok (8748453)
Kong Yeow Kang (17743178)
Sock Wen Ng (14167608)
Norazida Ab Rahman (12267122)
Muhammad Aminul Syahmi (17743181)
Mohan Dass Pathmanathan (9319777)
Maheshwara Rao Appannan (14076732)
Kalaiarasu M. Peariasamy (9319780)
Sheamini Sivasampu (3580265)

January 2024

Factors associated with development of post COVID-19 condition at 3 months interval.</p

Symptoms presence and the most common symptoms encountered during the acute phase of COVID-19.

Haneen Aldahleh (17364649)
Anwar Batieha (6884636)
Rasheed Elayyan (17364652)
Nour Abdo (4485796)
Ishtaiwi Abuzayed (17364655)
Shatha Albaik (17364658)
Yousef Shahin (12236702)
Akihiro Seita (779362)

November 2023

Symptoms presence and the most common symptoms encountered during the acute phase of COVID-19.</p

Prevalence N (%) of CYP who had a symptom (never, once, twice or thrice) at testing, at 3 months post-test, at 6 months post-test.

Terence Stephenson (3568832)
Snehal M. Pinto Pereira (14725336)
Manjula D. Nugawela (14725339)
Kelsey McOwat (13894193)
Ruth Simmons (558172)
Trudie Chalder (37639)
Tamsin Ford (492302)
Isobel Heyman (3579683)
Olivia V. Swann (14725342)
Lana Fox-Smith (14725345)
Natalia K. Rojas (14725348)
Emma Dalrymple (14725351)
Shamez N. Ladhani (4033334)
Roz Shafran (3579680)

March 2023

Prevalence N (%) of CYP who had a symptom (never, once, twice or thrice) at testing, at 3 months pos...

Prevalence and cumulative incidence of grade 2 or higher ALT elevation during the study period.

Jennifer Audsley (340686)
Eric C. Seaberg (340688)
Joe Sasadeusz (340689)
Gail V. Matthews (340690)
Anchalee Avihingsanon (340691)
Kiat Ruxrungtham (247724)
Kit Fairley (340692)
Robert Finlayson (340693)
Hyon S. Hwang (340694)
Margaret Littlejohn (340695)
Stephen Locarnini (340696)
Gregory J. Dore (205555)
Chloe L. Thio (201147)
Sharon R. Lewin (130160)

February 2013

Prevalence and cumulative incidence of grade 2 or higher ALT elevation during the study period.</...

Symptoms among contacts completing monitoring versus potential cases, six counties—Liberia, June 2014–July 2015.

Krista C. Swanson (5742404)
Chiara Altare (647899)
Chea Sanford Wesseh (4866715)
Tolbert Nyenswah (3804043)
Tashrik Ahmed (5742407)
Nir Eyal (2215588)
Esther L. Hamblion (4062442)
Justin Lessler (116180)
David H. Peters (347388)
Mathias Altmann (5012552)

September 2018

Symptoms among contacts completing monitoring versus potential cases, six counties—Liberia, June 201...

Baseline prevalence of infection, number of subjects eligible for follow-up, losses to follow-up and 18-month cumulative incidence of infection by type of intervention.

Guilherme L. Werneck (331080)
Carlos H. N. Costa (366149)
Fernando Aécio Amorim de Carvalho (652061)
Maria do Socorro Pires e Cruz (652062)
James H. Maguire (272682)
Marcia C. Castro (364589)

October 2014

Baseline prevalence of infection, number of subjects eligible for follow-up, losses to follow-up ...

Baseline clinical characteristics of patients who were followed up for 6 months.

Hiroki Okabe (14425179)
Yoshitaka Muraoka (14425182)
Yutaro Naka (14425185)
Koshi Setoyama (14425188)
Konosuke Inoue (14425191)
Toshiya Miura (14425194)
Akiyoshi Shimizu (14425197)
Reo Anai (14425200)
Tetsu Miyamoto (14425203)
Yuki Tsuda (6391430)
Masaru Araki (14425206)
Shinjo Sonoda (9291701)
Masaharu Kataoka (290909)

January 2023

Baseline clinical characteristics of patients who were followed up for 6 months.</p

Incidence rates of symptoms during all the period of study by athlete status.

Natalia Rodriguez-Valero (5675603)
Miguel Luengo Oroz (5675606)
Daniel Cuadrado Sanchez (5675609)
Alexander Vladimirov (5675612)
Marina Espriu (5675615)
Isabel Vera (5675618)
Sergi Sanz (89754)
Jose Luis Gonzalez Moreno (5675621)
Jose Muñoz (3343469)
Maria Jesus Ledesma Carbayo (5675624)

August 2018

Incidence rates of symptoms during all the period of study by athlete status.</p

Disease and symptom prevalence estimates including 95% confidence intervals and unadjusted odds ratios.

H. Felix Fischer (457925)
Sylvia Binting (457926)
Angelina Bockelbrink (436852)
Peter Heusser (397715)
Christoph Hueck (457927)
Thomas Keil (177240)
Stephanie Roll (168590)
Claudia Witt (457928)

September 2013

Disease and symptom prevalence estimates including 95% confidence intervals and unadjusted odds r...

Fig 3 -

Terence Stephenson (3568832)
Snehal M. Pinto Pereira (14725336)
Manjula D. Nugawela (14725339)
Kelsey McOwat (13894193)
Ruth Simmons (558172)
Trudie Chalder (37639)
Tamsin Ford (492302)
Isobel Heyman (3579683)
Olivia V. Swann (14725342)
Lana Fox-Smith (14725345)
Natalia K. Rojas (14725348)
Emma Dalrymple (14725351)
Shamez N. Ladhani (4033334)
Roz Shafran (3579680)

March 2023

Symptoms with overall prevalence declining from baseline to 6 months post-test in test-positives*.</...

Distribution of symptoms at 3 months among study participants with post COVID-19 condition (n = 1,510).

Peter Seah Keng Tok (8748453)
Kong Yeow Kang (17743178)
Sock Wen Ng (14167608)
Norazida Ab Rahman (12267122)
Muhammad Aminul Syahmi (17743181)
Mohan Dass Pathmanathan (9319777)
Maheshwara Rao Appannan (14076732)
Kalaiarasu M. Peariasamy (9319780)
Sheamini Sivasampu (3580265)

January 2024

Distribution of symptoms at 3 months among study participants with post COVID-19 condition (n = 1,51...

Percentage of self-reported Long COVID symptoms at four weeks and six months of follow-up.

M. C. Arjun (14285136)
Arvind Kumar Singh (8808743)
Debkumar Pal (14285139)
Kajal Das (12895698)
Alekhya G. (14285142)
Mahalingam Venkateshan (14207855)
Baijayantimala Mishra (14285145)
Binod Kumar Patro (10151285)
Prasanta Raghab Mohapatra (10151300)
Sonu Hangma Subba (5689889)

December 2022

Percentage of self-reported Long COVID symptoms at four weeks and six months of follow-up.</p

Prevalence of metabolic syndrome, at baseline, three and six months, by randomization group.

Lotte van Dammen (4759953)
Vincent Wekker (4759959)
Anne M. van Oers (4759983)
Meike A. Q. Mutsaerts (4759980)
Rebecca C. Painter (4759956)
Aeilko H. Zwinderman (93416)
Henk Groen (444146)
Cornelieke van de Beek (4759974)
Anneke C. Muller Kobold (128867)
Walter K. H. Kuchenbecker (4759977)
Ron van Golde (4759965)
Gerrit J. E. Oosterhuis (4759968)
Niels E. A. Vogel (4759971)
Ben Willem J. Mol (3090126)
Tessa J. Roseboom (501394)
Annemieke Hoek (4759962)

January 2018

Prevalence of metabolic syndrome, at baseline, three and six months, by randomization group.</p

Prevalence of symptoms associated with AOM in children enrolled at baseline (day 0).

Penelope Abbott (3502094)
Caitlin Frede (14670762)
Wendy C. Y. Hu (10907179)
Sanja Lujic (316280)
Steven Trankle (7048088)
Letitia Campbell (12421633)
Hasantha Gunasekera (8295636)
Robyn Walsh (14670765)
Amanda J. Leach (12415702)
Peter Morris (86687)
Kelvin Kong (10983062)
Jennifer Reath (5572118)

February 2023

Prevalence of symptoms associated with AOM in children enrolled at baseline (day 0).</p

Prevalence (%) of symptoms in patients with different conditions at baseline interview.

Irene J. Higginson (121358)
Wei Gao (2085)
Tariq Zaffer Saleem (121362)
K. Ray Chaudhuri (121366)
Rachel Burman (50700)
Paul McCrone (121370)
Peter Nigel Leigh (121374)

November 2012

Prevalence (%) of symptoms in patients with different conditions at baseline interview.</p

Factors associated with development of post COVID-19 condition at 3 months interval.

Peter Seah Keng Tok (8748453)
Kong Yeow Kang (17743178)
Sock Wen Ng (14167608)
Norazida Ab Rahman (12267122)
Muhammad Aminul Syahmi (17743181)
Mohan Dass Pathmanathan (9319777)
Maheshwara Rao Appannan (14076732)
Kalaiarasu M. Peariasamy (9319780)
Sheamini Sivasampu (3580265)

January 2024

Factors associated with development of post COVID-19 condition at 3 months interval.</p

Symptoms presence and the most common symptoms encountered during the acute phase of COVID-19.

Haneen Aldahleh (17364649)
Anwar Batieha (6884636)
Rasheed Elayyan (17364652)
Nour Abdo (4485796)
Ishtaiwi Abuzayed (17364655)
Shatha Albaik (17364658)
Yousef Shahin (12236702)
Akihiro Seita (779362)

November 2023

Symptoms presence and the most common symptoms encountered during the acute phase of COVID-19.</p

Prevalence N (%) of CYP who had a symptom (never, once, twice or thrice) at testing, at 3 months post-test, at 6 months post-test.

Terence Stephenson (3568832)
Snehal M. Pinto Pereira (14725336)
Manjula D. Nugawela (14725339)
Kelsey McOwat (13894193)
Ruth Simmons (558172)
Trudie Chalder (37639)
Tamsin Ford (492302)
Isobel Heyman (3579683)
Olivia V. Swann (14725342)
Lana Fox-Smith (14725345)
Natalia K. Rojas (14725348)
Emma Dalrymple (14725351)
Shamez N. Ladhani (4033334)
Roz Shafran (3579680)

March 2023

Prevalence N (%) of CYP who had a symptom (never, once, twice or thrice) at testing, at 3 months pos...

Prevalence and cumulative incidence of grade 2 or higher ALT elevation during the study period.

Jennifer Audsley (340686)
Eric C. Seaberg (340688)
Joe Sasadeusz (340689)
Gail V. Matthews (340690)
Anchalee Avihingsanon (340691)
Kiat Ruxrungtham (247724)
Kit Fairley (340692)
Robert Finlayson (340693)
Hyon S. Hwang (340694)
Margaret Littlejohn (340695)
Stephen Locarnini (340696)
Gregory J. Dore (205555)
Chloe L. Thio (201147)
Sharon R. Lewin (130160)

February 2013

Prevalence and cumulative incidence of grade 2 or higher ALT elevation during the study period.</...

Symptoms among contacts completing monitoring versus potential cases, six counties—Liberia, June 2014–July 2015.

Krista C. Swanson (5742404)
Chiara Altare (647899)
Chea Sanford Wesseh (4866715)
Tolbert Nyenswah (3804043)
Tashrik Ahmed (5742407)
Nir Eyal (2215588)
Esther L. Hamblion (4062442)
Justin Lessler (116180)
David H. Peters (347388)
Mathias Altmann (5012552)

September 2018

Symptoms among contacts completing monitoring versus potential cases, six counties—Liberia, June 201...

Baseline prevalence of infection, number of subjects eligible for follow-up, losses to follow-up and 18-month cumulative incidence of infection by type of intervention.

Guilherme L. Werneck (331080)
Carlos H. N. Costa (366149)
Fernando Aécio Amorim de Carvalho (652061)
Maria do Socorro Pires e Cruz (652062)
James H. Maguire (272682)
Marcia C. Castro (364589)

October 2014

Baseline prevalence of infection, number of subjects eligible for follow-up, losses to follow-up ...

Baseline clinical characteristics of patients who were followed up for 6 months.

Hiroki Okabe (14425179)
Yoshitaka Muraoka (14425182)
Yutaro Naka (14425185)
Koshi Setoyama (14425188)
Konosuke Inoue (14425191)
Toshiya Miura (14425194)
Akiyoshi Shimizu (14425197)
Reo Anai (14425200)
Tetsu Miyamoto (14425203)
Yuki Tsuda (6391430)
Masaru Araki (14425206)
Shinjo Sonoda (9291701)
Masaharu Kataoka (290909)

January 2023

Baseline clinical characteristics of patients who were followed up for 6 months.</p

Incidence rates of symptoms during all the period of study by athlete status.

Natalia Rodriguez-Valero (5675603)
Miguel Luengo Oroz (5675606)
Daniel Cuadrado Sanchez (5675609)
Alexander Vladimirov (5675612)
Marina Espriu (5675615)
Isabel Vera (5675618)
Sergi Sanz (89754)
Jose Luis Gonzalez Moreno (5675621)
Jose Muñoz (3343469)
Maria Jesus Ledesma Carbayo (5675624)

August 2018

Incidence rates of symptoms during all the period of study by athlete status.</p

Disease and symptom prevalence estimates including 95% confidence intervals and unadjusted odds ratios.

H. Felix Fischer (457925)
Sylvia Binting (457926)
Angelina Bockelbrink (436852)
Peter Heusser (397715)
Christoph Hueck (457927)
Thomas Keil (177240)
Stephanie Roll (168590)
Claudia Witt (457928)

September 2013

Disease and symptom prevalence estimates including 95% confidence intervals and unadjusted odds r...

Symptoms with overall prevalence increasing from baseline to 3 months and increasing or remaining high at 6 months.

Abstract

Extracted data

Symptoms with overall prevalence increasing from baseline to 3 months and increasing or remaining high at 6 months.

Abstract

Extracted data

Related items

Related items